NCT01863485View on ClinicalTrials.gov

Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

May 31, 2016

Conditions
Advanced Cancer
Interventions
DRUG

CM082 Tablet

CM082 tablets taken orally once a day on 28-day cycles

Trial Locations (3)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

100034

Beijing University First Hospital, Beijing

300060

Tianjin Cancer Hospital, Tianjin

Sponsors

Lead Sponsor

AnewPharma
All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

AnewPharma

INDUSTRY

NCT01863485 - Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China | Biotech Hunter | Biotech Hunter